Late-breaking Trials from the 2016 American Heart Association's Scientific Sessions.

MedStar author(s):
Citation: Cardiovascular Revascularization Medicine. 18(1):70-74, 2017 Jan - FebPMID: 28131332 Institution: MedStar Heart & Vascular InstituteForm of publication: Journal ArticleMedline article type(s): CongressesSubject headings: *Biomedical Research | *Cardiology | *Cardiovascular Diseases/th [Therapy] | Cardiovascular Diseases/di [Diagnosis] | Cardiovascular Diseases/mo [Mortality] | Cardiovascular Diseases/pp [Physiopathology] | Clinical Trials as Topic | Humans | Treatment OutcomeYear: 2017Local holdings: Available in print through MWHC library: 2002 - presentISSN:
  • 1878-0938
Name of journal: Cardiovascular revascularization medicine : including molecular interventionsAbstract: Copyright © 2016. Published by Elsevier Inc.The late breaking trials released at the American Heart Association scientific sessions conference in November in New Orleans, LA covered a wide range of topics, including new devices within the field of heart failure, new registry data on transcatheter aortic valve replacement (TAVR) in intermediate risk patients, and medical management of peripheral arterial disease, coronary artery disease, and hypercholesterolemia. The following review highlights the late breaking trials presented at the conference that will have significant impact on clinical practice.All authors: Alraies MC, Buchanan KD, Kajita AH, Koifman E, Rogers T, Steinvil AFiscal year: FY2017Digital Object Identifier: Date added to catalog: 2017-04-10
Holdings
Item type Current library Collection Call number Status Date due Barcode
Journal Article MedStar Authors Catalog Article 28131332 Available 28131332

Available in print through MWHC library: 2002 - present

Copyright © 2016. Published by Elsevier Inc.

The late breaking trials released at the American Heart Association scientific sessions conference in November in New Orleans, LA covered a wide range of topics, including new devices within the field of heart failure, new registry data on transcatheter aortic valve replacement (TAVR) in intermediate risk patients, and medical management of peripheral arterial disease, coronary artery disease, and hypercholesterolemia. The following review highlights the late breaking trials presented at the conference that will have significant impact on clinical practice.

English

Powered by Koha